Lineage Cell Therapeutics Q2 2026 net income $1.5M; cash runway to Q3 2028

Lineage Cell Therapeutics, Inc.

Q2 2026 net income of $1.5M ($0.01 basic EPS) vs net loss of $30.5M in Q2 2025; revenue $1.1M, down from $2.8M.
Cash $50.8M expected to fund operations into Q3 2028.
RG6501 (OpRegen) Phase 1/2a 3-year data showed sustained BCVA gains and retinal structure restoration in Cohort 4.
COR1 corneal endothelial cell therapy program advanced to in-vivo animal testing; initial data expected in 2026.
Established Scientific Advisory Board with Joachim Fruebis, PhD as founding member.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.